Organon & Co(OGN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

OGN Organon & Co

盘前交易 03-10 05:17:41 EDT

6.53

-0.03

-0.46%

最高6.57	最低6.34	成交量376.42万
今开6.50	昨收6.56	日振幅3.51%
总市值16.98亿	流通市值16.90亿	总股本2.60亿
成交额2,443万	换手率1.45%	流通股本2.59亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"OGN","market":"US","secType":"STK","nameCN":"Organon & Co","latestPrice":6.53,"timestamp":1773086400000,"preClose":6.56,"halted":0,"volume":3764230,"delay":0,"changeRate":-0.00457317073170722,"floatShares":258733290,"shares":259982912,"eps":0.72,"marketStatus":"盘前交易","change":-0.03,"latestTime":"03-10 05:17:41 EDT","open":6.5,"high":6.57,"low":6.34,"amount":24433598.10885,"amplitude":0.035061,"askPrice":7.03,"askSize":200,"bidPrice":6.52,"bidSize":150,"shortable":3,"etf":0,"ttmEps":0.72,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773149400000},"marketStatusCode":1,"adr":0,"exchange":"NYSE","adjPreClose":6.53,"dividendRate":0.012251,"postHourTrading":{"tag":"盘后","latestPrice":6.63,"preClose":6.53,"latestTime":"19:31 EDT","volume":67044,"amount":437752.48,"timestamp":1773099095152,"change":0.1,"changeRate":0.015314,"amplitude":0.039816},"volumeRatio":1.3354925551903634,"impliedVol":0.5826,"impliedVolPercentile":0.196},"requestUrl":"/m/hq/s/OGN","defaultTab":"news","newsList":[{"id":"1187634909","title":"Organon与Sebela制药达成协议，获授权引进无激素宫内节育器Miudella®","url":"https://stock-news.laohu8.com/highlight/detail?id=1187634909","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187634909?lang=zh_cn&edition=full","pubTime":"2026-02-23 20:30","pubTimestamp":1771849813,"startTime":"0","endTime":"0","summary":"Organon & Co（简称：Organon）已正式签署协议，获得Sebela Pharmaceuticals旗下无激素宫内节育器Miudella®的授权许可。此次合作将拓展Organon在女性健康领域的产品组合，为全球女性提供更多避孕选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","LU2065171402.SGD","OGN","LU2065169927.USD","BK4559","LU2065171311.SGD","BK4588","BK4007","BK4585"],"gpt_icon":0},{"id":"1121548213","title":"独立审查确认生物类似药采购无虞 Organon股价应声上涨1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1121548213","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121548213?lang=zh_cn&edition=full","pubTime":"2026-02-20 22:31","pubTimestamp":1771597898,"startTime":"0","endTime":"0","summary":"在第三方独立审查机构公布对Organon历史生物类似药采购流程的评估结果后，该公司股价今日呈现显著上扬态势。审查报告明确指出，其过往采购操作符合规范要求，未发现任何违规行为。这一结论消除了市场对潜在合规风险的疑虑，投资者信心随之提振。\n受此利好消息影响，Organon股票当日收盘涨幅达1.7%，成交量同步放大。生物类似药作为公司战略布局的重要板块，此次审查结果为其后续业务拓展奠定了合规基础。市场分析师认为，该公告有效缓解了投资者对监管风险的担忧，为企业估值修复提供了支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","LU2065171311.SGD","BK4588","BK4585","LU2065169927.USD","LU2065170008.USD","OGN","BK4007","LU2065171402.SGD"],"gpt_icon":0},{"id":"1121700994","title":"Organon & Co独立审查：未发现往年从供应商处采购生物类似药时机存在不当行为的证据","url":"https://stock-news.laohu8.com/highlight/detail?id=1121700994","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121700994?lang=zh_cn&edition=full","pubTime":"2026-02-20 20:38","pubTimestamp":1771591094,"startTime":"0","endTime":"0","summary":"一项针对Organon & Co的独立审查结果显示，调查方未找到任何证据，能够证明该公司在往年从供应商处采购生物类似药的时机选择上存在不当行为。此次审查旨在澄清相关采购操作的时间点是否合规，最终结论表明，未发现存在问题的依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2065171402.SGD","BK4588","LU2065169927.USD","BK4007","LU2065170008.USD","OGN","LU2065171311.SGD","BK4559"],"gpt_icon":0},{"id":"1187621050","title":"异动解读 | 第四季度利润与营收双双不及预期，Organon盘前大跌10.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=1187621050","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187621050?lang=zh_cn&edition=full","pubTime":"2026-02-12 21:20","pubTimestamp":1770902424,"startTime":"0","endTime":"0","summary":"Organon & Co (OGN) 今日盘前股价大幅下挫10.84%，市场表现引发关注。消息面上，该公司公布的第四季度业绩表现疲软。财报显示，其第四季度调整后利润为每股63美分，低于市场预期的每股73美分；同时，第四季度营收为15亿美元，也低于预期的15.4亿美元。利润与营收双双不及预期，是导致股价在盘前交易时段承压大跌的主要原因。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["OGN"],"gpt_icon":0},{"id":"1175621004","title":"财报前瞻｜Organon & Co本季度营收预计小幅下滑，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1175621004","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175621004?lang=zh_cn&edition=full","pubTime":"2026-02-05 11:24","pubTimestamp":1770261845,"startTime":"0","endTime":"0","summary":"Organon & Co将于2026年02月12日发布最新季度财报，市场关注收入动能与盈利质量的变化，以及核心品类的结构调整带来的影响。市场普遍预期Organon & Co本季度营收为15.39亿美元，同比下降3.45%；息税前利润为3.80亿美元，同比下降7.34%；调整后每股收益为0.73美元，同比下降15.43%。上季度Organon & Co实现营收16.02亿美元，同比增长1.26%；毛利率54.24%；归属母公司的净利润1.60亿美元，净利率9.99%，环比增长10.34%；调整后每股收益1.01美元，同比增长16.09%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻｜Organon & Co本季度营收预计小幅下滑，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OGN"],"gpt_icon":0},{"id":"1153205452","title":"欧加农公司宣布美国FDA批准补充新药申请，延长Nexplanon®（依托孕烯植入剂）68毫克不透射线产品的使用期限","url":"https://stock-news.laohu8.com/highlight/detail?id=1153205452","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153205452?lang=zh_cn&edition=full","pubTime":"2026-01-17 10:12","pubTimestamp":1768615963,"startTime":"0","endTime":"0","summary":"欧加农公司近日宣布，其补充新药申请已获得美国食品药品监督管理局（FDA）的批准。此次获批意味着Nexplanon®（依托孕烯植入剂）68毫克不透射线产品的使用期限得以延长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OGN","BK4588","BK4559","LU2065171402.SGD","LU2065169927.USD","LU2065170008.USD","LU2065171311.SGD","BK4007","BK4585"],"gpt_icon":0},{"id":"1136506367","title":"Organon与第一三共达成Nilemdo®在法国、丹麦、冰岛、瑞典、芬兰及挪威商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1136506367","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136506367?lang=zh_cn&edition=full","pubTime":"2026-01-08 14:33","pubTimestamp":1767854021,"startTime":"0","endTime":"0","summary":"Organon & Co近日宣布与日本制药巨头第一三共签署重要商业合作协议，获得其降胆固醇药物Nilemdo在法国、丹麦、冰岛、瑞典、芬兰和挪威六个欧洲国家的独家商业化权利。此次合作将显著拓展Organon在欧洲心血管疾病治疗领域的产品组合，同时强化第一三共创新药物在全球市场的渗透力。这一战略布局不仅彰显Organon对欧洲高价值医药市场的深耕决心，更凸显其通过外部合作快速扩充特色药品管线的商业模式。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","OGN","LU2065171402.SGD","BK4585","BK4588","LU2065170008.USD","BK4559","LU2065169927.USD","BK4007"],"gpt_icon":0},{"id":"1155289447","title":"Henlius与Organon宣布美国FDA批准Poherdy®（Pertuzumab-Dpzb），首个在美国获批的Perjeta（Pertuzumab）生物类似药","url":"https://stock-news.laohu8.com/highlight/detail?id=1155289447","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155289447?lang=zh_cn&edition=full","pubTime":"2025-11-17 18:32","pubTimestamp":1763375530,"startTime":"0","endTime":"0","summary":"Henlius与Organon宣布，美国FDA已批准Poherdy®（Pertuzumab-Dpzb），这是首个在美国获批的Perjeta（Pertuzumab）生物类似药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","LU2065171311.SGD","LU2065169927.USD","LU2065170008.USD","BK4559","BK4588","BK4585","BK4007","OGN"],"gpt_icon":0},{"id":"2584399624","title":"Organon & Co.2025财年第三财季实现净利润1.60亿美元，同比减少55.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584399624","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584399624?lang=zh_cn&edition=full","pubTime":"2025-11-17 00:01","pubTimestamp":1763308866,"startTime":"0","endTime":"0","summary":"11月17日，Organon & Co.公布财报，公告显示公司2025财年第三财季净利润为1.60亿美元，同比减少55.43%；其中营业收入为16.02亿美元，同比增加1.26%，每股基本收益为0.62美元。从资产负债表来看，Organon & Co.总负债126.46亿美元，其中短期债务45.00百万美元，资产负债比为1.08，流动比率为1.76。机构评级：截至2025年11月17日，当前有6家机构对Organon & Co.目标价做出预测，其中目标均价为9.67美元，其中最低目标价为5.00美元，最高目标价为12.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117000126a6fd6c9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117000126a6fd6c9b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["OGN"],"gpt_icon":0},{"id":"1181983631","title":"异动解读 | 摩根大通下调目标价，Organon & Co盘中大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181983631","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181983631?lang=zh_cn&edition=full","pubTime":"2025-11-11 23:34","pubTimestamp":1762875267,"startTime":"0","endTime":"0","summary":"周二盘中，Organon & Co股价出现大幅下跌，跌幅达5.06%，引发投资者关注。造成股价下跌的主要原因可能是华尔街知名投行摩根大通对该公司股票的最新评估。根据最新报告，摩根大通分析师将Organon & Co的目标价从14美元下调至12美元。投资者可能会根据这一新的分析调整其投资策略，导致抛售压力增加。Organon & Co今日的股价大跌似乎直接反映了市场对这一分析师评级变化的反应。投资者应密切关注公司未来的财务表现和市场动态，以评估这一下跌是否会持续。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["OGN"],"gpt_icon":0},{"id":"1186695436","title":"Organon 股价在盘前上涨 1.8%，因公司宣布与 Laborie 达成协议，将其 Jada 系统以高达 4.65 亿美元出售","url":"https://stock-news.laohu8.com/highlight/detail?id=1186695436","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186695436?lang=zh_cn&edition=full","pubTime":"2025-11-07 20:36","pubTimestamp":1762518985,"startTime":"0","endTime":"0","summary":"Organon 股价在盘前上涨 1.8%，因公司宣布与 Laborie 达成协议，将其 Jada 系统以高达 4.65 亿美元出售。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU2065169927.USD","LU2065170008.USD","LU2065171402.SGD","BK4588","BK4559","LU2065171311.SGD","OGN","BK4585"],"gpt_icon":0},{"id":"2578981199","title":"Organon(OGN.US)因内部控制问题重挫，再遭Piper Sandler大砍目标价至5美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2578981199","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578981199?lang=zh_cn&edition=full","pubTime":"2025-10-28 14:45","pubTimestamp":1761633937,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Piper Sandler将Organon的评级从“增持”下调至“减持”，并将目标股价从 18 美元下调至 5 美元。此次行动是在审计委员会对公司进行调查之后采取的，该调查揭露了公司在其避孕产品“Nexplanon”方面存在重大内部控制缺陷，导致 2022 年、2024 年和 2025 年的财务报表出现错误陈述。周一，该公司股价收跌约23%。此次评级下调表明，Piper Sandler认为Organon的复苏之路漫长，这主要是由于需要恢复内部控制和投资者信心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1361142.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Organon(OGN.US)因内部控制问题重挫，再遭Piper Sandler大砍目标价至5美元","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["OGN"],"gpt_icon":0},{"id":"1143846624","title":"Organon股价创历史新低，首席执行官Kevin Ali因避孕植入物销售调查辞职，股价最终下跌21%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143846624","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143846624?lang=zh_cn&edition=full","pubTime":"2025-10-27 21:39","pubTimestamp":1761572352,"startTime":"0","endTime":"0","summary":"Organon股价创历史新低，首席执行官Kevin Ali因避孕植入物销售调查辞职，股价最终下跌21%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","BK4585","BK4559","LU2065170008.USD","BK4007","LU2065171311.SGD","LU2065171402.SGD","BK4588","OGN"],"gpt_icon":0},{"id":"1136210617","title":"Organon股价盘前下跌17.5%，因首席执行官Kevin Ali因避孕植入物销售调查辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=1136210617","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136210617?lang=zh_cn&edition=full","pubTime":"2025-10-27 20:09","pubTimestamp":1761566953,"startTime":"0","endTime":"0","summary":"Organon股价盘前下跌17.5%，因首席执行官Kevin Ali因避孕植入物销售调查辞职。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2065170008.USD","OGN","BK4559","LU2065169927.USD","LU2065171311.SGD","BK4007","BK4588","LU2065171402.SGD"],"gpt_icon":0},{"id":"1156321012","title":"Organon & Co：不当的Nexplanon销售行为使公司能够达到指导目标和某些外部收入预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1156321012","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156321012?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:40","pubTimestamp":1761565215,"startTime":"0","endTime":"0","summary":"Organon & Co：不当的Nexplanon销售行为使公司能够达到指导目标和某些外部收入预期","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2065171402.SGD","BK4588","LU2065169927.USD","BK4007","LU2065170008.USD","OGN","LU2065171311.SGD","BK4559"],"gpt_icon":0},{"id":"1169579286","title":"Organon & Co: 目前发现不需要对以往财务报表进行重述或修订","url":"https://stock-news.laohu8.com/highlight/detail?id=1169579286","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169579286?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:34","pubTimestamp":1761564864,"startTime":"0","endTime":"0","summary":"Organon & Co: 目前发现不需要对以往财务报表进行重述或修订","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2065169927.USD","BK4585","LU2065171402.SGD","OGN","BK4559","LU2065170008.USD","LU2065171311.SGD","BK4007"],"gpt_icon":0},{"id":"1188215591","title":"Organon & Co：启动寻找常任首席执行官的工作，包括内部和外部候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=1188215591","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188215591?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:34","pubTimestamp":1761564856,"startTime":"0","endTime":"0","summary":"Organon & Co：启动寻找常任首席执行官的工作，包括内部和外部候选人","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065170008.USD","LU2065171311.SGD","LU2065169927.USD","OGN","LU2065171402.SGD","BK4559","BK4585","BK4007","BK4588"],"gpt_icon":0},{"id":"1118094156","title":"Organon：调查发现Nexplanon销售额在截至2022年12月31日或2024年12月31日的年度中占公司合并收入的比例不足1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1118094156","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118094156?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:34","pubTimestamp":1761564856,"startTime":"0","endTime":"0","summary":"Organon：调查发现Nexplanon销售额在截至2022年12月31日或2024年12月31日的年度中占公司合并收入的比例不足1%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","OGN","LU2065171402.SGD","BK4585","BK4588","LU2065170008.USD","BK4559","LU2065169927.USD","BK4007"],"gpt_icon":0},{"id":"1169861830","title":"Organon \\u0026 Co：采取补救措施以改善财务控制并解决任何重大缺陷","url":"https://stock-news.laohu8.com/highlight/detail?id=1169861830","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169861830?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:34","pubTimestamp":1761564854,"startTime":"0","endTime":"0","summary":"Organon \\u0026 Co：采取补救措施以改善财务控制并解决任何重大缺陷","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2065171311.SGD","BK4588","OGN","LU2065171402.SGD","BK4559","LU2065170008.USD","BK4007","LU2065169927.USD"],"gpt_icon":0},{"id":"1158170986","title":"Organon: 调查发现美国部分批发商被要求在2022年第四季度末、2024年第三和第四季度、2025年第一、第二和第三季度购买超过需求的Nexplanon","url":"https://stock-news.laohu8.com/highlight/detail?id=1158170986","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158170986?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:33","pubTimestamp":1761564790,"startTime":"0","endTime":"0","summary":"Organon: 调查发现美国部分批发商被要求在2022年第四季度末、2024年第三和第四季度、2025年第一、第二和第三季度购买超过需求的Nexplanon","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","BK4585","BK4559","LU2065170008.USD","BK4007","LU2065171311.SGD","LU2065171402.SGD","BK4588","OGN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.organon.com","stockEarnings":[{"period":"1week","weight":-0.0918},{"period":"1month","weight":-0.2046},{"period":"3month","weight":-0.0604},{"period":"6month","weight":-0.3635},{"period":"1year","weight":-0.5771},{"period":"ytd","weight":-0.0893}],"compareEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":-0.0179},{"period":"3month","weight":-0.007},{"period":"6month","weight":0.04},{"period":"1year","weight":0.1777},{"period":"ytd","weight":-0.0054}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Organon & Co.是一家特拉华州公司，成立于2020年3月11日。Organon是一家基于科学的全球制药公司，通过一系列针对女性健康，生物仿制药和知名品牌的处方疗法，开发并提供创新的健康解决方案。他们的使命是成为世界领先的女性保健公司，每天为每个女性提供更好，更健康的服务。他们计划利用自身在生殖健康方面的优势，建立一系列健康解决方案，为从青春期到更年期及以后的妇女提供服务。","yearOnYearQuotes":[{"month":1,"riseRate":1,"avgChangeRate":0.103066},{"month":2,"riseRate":0.4,"avgChangeRate":-0.031967},{"month":3,"riseRate":0.2,"avgChangeRate":-0.025931},{"month":4,"riseRate":0.25,"avgChangeRate":-0.042245},{"month":5,"riseRate":0.5,"avgChangeRate":-0.044845},{"month":6,"riseRate":0.5,"avgChangeRate":-0.004329},{"month":7,"riseRate":0.6,"avgChangeRate":0.002574},{"month":8,"riseRate":0.4,"avgChangeRate":0.012058},{"month":9,"riseRate":0.2,"avgChangeRate":-0.086411},{"month":10,"riseRate":0.4,"avgChangeRate":-0.058949},{"month":11,"riseRate":0.2,"avgChangeRate":-0.091617},{"month":12,"riseRate":0.6,"avgChangeRate":0.051819}],"exchange":"NYSE","name":"Organon & Co","nameEN":"Organon & Co"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Organon & Co(OGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Organon & Co(OGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Organon & Co,OGN,Organon & Co股票,Organon & Co股票老虎,Organon & Co股票老虎国际,Organon & Co行情,Organon & Co股票行情,Organon & Co股价,Organon & Co股市,Organon & Co股票价格,Organon & Co股票交易,Organon & Co股票购买,Organon & Co股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Organon & Co(OGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Organon & Co(OGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}